Recombinant Human Insulin-like growth factor I [HSA:3479] [KO:K05459]
Treatment of amyotrophic lateral sclerosis, Treatment of diabetes mellitus (types I and types II), Treatment of growth hormone insensitivity (GHIS)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
H01AC Somatropin and somatropin agonists
H01AC03 Mecasermin
D03297 Mecasermin (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D03297 Mecasermin (USAN/INN); Mecasermin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
INSR family
IGF1R (CD221)
D03297 Mecasermin (USAN/INN) <JP/US>
Cytokines and receptors
Cytokine receptors
CSF and other factor receptors
GHR
D03297 Mecasermin (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03297
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03297
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03297
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D03297
